Stock Alert: Lyra Therapeutics Tanks 20%

Shares of Lyra Therapeutics, Inc. (LYRA) are tanking over 20% on Monday morning despite positive topline results from phase 2 study of LYR-210 for chronic rhinosinusitis.

LYRA is currently trading at $9.55, down $2.92 or 23.42%, on the Nasdaq.

7500 mcg dose of LYR-210 achieved statistically significant improvement in a composite of the 4 cardinal symptoms of CRS at weeks 16, 20 and 24 compared to control.

"These data are yet more remarkable given it was achieved during the COVID-19 pandemic, which caused us to curtail enrollment sooner than originally planned," said Maria Palasis, CEO of Lyra Therapeutics.

The US stock market are down on Monday morning as investors are worried about rising coronavirus cases.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla CEO Elon Musk announced that the luxury electric vehicle maker has started the production of Tesla Semi electric trucks, and the first delivery will be to food and beverages giant Pepsico Inc. starting December 1. In a tweet, Musk said, "Excited to announce start of production of Tesla Semi Truck with deliveries to @Pepsi on Dec 1st!" Ford Motor is increasing the entry-level price of its electric F-150 Lightning pickup citing rising costs and supply chain issues amid increasing demand. This is the second price hike after a recent increase in August. The starting price of the 2023 model year pickup will be raised by $5,000 by October 24, reports said citing an email statement. Constellation Brands, Inc. (STZ) said it delivered another quarter of strong business performance. Beer Business achieved double-digit net sales growth for the quarter, while Wine and Spirits net sales rose 1%. The solid top-line performance of its Beer and Wine and Spirits Businesses in the first half...
Follow RTT